NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Buy" from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $42.89.

Several analysts recently issued reports on NAMS shares. Needham & Company LLC reiterated a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Citigroup began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They set a "buy" rating and a $42.00 price objective on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target for the company.

Insiders Place Their Bets

In related news, Director James N. Topper acquired 8,584 shares of the company's stock in a transaction dated Monday, June 16th. The shares were bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the transaction, the director directly owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This trade represents a 0.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Douglas F. Kling sold 100,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the transaction, the chief operating officer owned 44,000 shares in the company, valued at approximately $848,760. This trade represents a 69.44% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 12,364 shares of company stock valued at $236,839. Company insiders own 20.84% of the company's stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of large investors have recently made changes to their positions in NAMS. Mirae Asset Global Investments Co. Ltd. grew its holdings in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after buying an additional 596 shares in the last quarter. Legal & General Group Plc boosted its position in shares of NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock valued at $590,000 after acquiring an additional 4,556 shares during the period. American Century Companies Inc. acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at about $8,907,000. Swiss National Bank increased its position in NewAmsterdam Pharma by 105.1% during the fourth quarter. Swiss National Bank now owns 72,000 shares of the company's stock worth $1,850,000 after acquiring an additional 36,900 shares during the period. Finally, Northern Trust Corp bought a new position in NewAmsterdam Pharma during the fourth quarter worth about $556,000. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Down 2.2%

NASDAQ NAMS opened at $21.54 on Monday. The firm's 50 day moving average is $19.10 and its 200-day moving average is $20.29. The company has a market capitalization of $2.42 billion, a PE ratio of -11.46 and a beta of -0.03. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The business had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.